CDMO Sterling Pharma Solutions has announced what it called the next phase of a multi-year investment strategy at its site in Dudley, UK. It will spend £10 million by mid-2022 on new process development laboratories and commercial-scale manufacturing equipment to meet growth in demand for small molecule API manufacturing.
CDMO Sterling Pharma Solutions has completed the initial phase of investment in its centre of excellence for research into the commercial applications of continuous flow chemistry at Dudley, UK. This follows the appointment in July of Professor Ian Baxendale of Durham University to head a dedicated team in this field.
CDMOs Sterling Pharma Solutions and Novasep have both made announcements in the high potency arena in the past week. The former has signed a manufacturing deal with oncology specialist OncoTex, while the latter is expanding its main high potency API (HPAPI) site at Le Mans.
Pharmaceutical CDMO Sterling Pharma Solutions which is based near Newcastle-upon-Tyne, UK, and was formerly owned by Rhodia and Shasun, has acquired Alcami’s facility at Germantown, Wisconsin (pictured). Terms were not disclosed.
Sterling said that this will boost its API development and manufacturing capacity, particularly for complex and hazardous requirements, and including high potency. Germantown has cGMP development, scale-up and manufacturing facilities with specialist expertise in handling technologies including plant-scale hydrogenation and cryogenic reactions.